A new oral mercurial diuretic, Merpurate, was studied in dogs for chronic toxicity and in humans for effectiveness. It was found that this product was effective as a diuretic in the doses used and gave a minimal number of undesirable reactions.
always been a therapeutic goal.
Diuresis could then be accomplished at a slow but regular rate, with the avoidance of a sudden profuse diuresis,' which is very uncomfortable for the patient, and produces marked alteration of the fluid and electrolyte balance. Rapid diuresis has been known to cause attacks of gout,2 tetany,3 and cerebral thrombosis.4 It has caused the low salt syndrome, and overdigitalization. Hence, slow diuresis is of some importance. Furthermore, oral diuretics avoid the necessity of frequent visits to the doctor and the financial burden thereof. They also eliminate the distasteful injections and allow the patient to handle his own care within safe limits.
The general recognition of the need of a safe and good oral diuretic without undesirable side effects is shown by the great number that have appeared upon the therapeutic scene in a relatively short span of time.
PHARMACOLOGY
Newer mercurial diuretics have been prepared from older agents by changing the mercury linkage in the molecule as well as by combining it with various members of the xanthine diuretics.
Merpurate,* chemically, is the hydrated crystalline double salt of calcium N- (3- They had all been digitalized, and were on a low salt diet. Each patient had been receiving at least one mercurial diuretic injection weekly in order to maintain cardiac compensation. All the patients in the study were ambulatory. MIost of them were from the Cardiac Clinic of the Newark Beth Israel Hospital, but several were private patients.
Mercurial injections were stopped on all patients and the oral tablets was substituted. A low salt diet and digitalis therapy were maintained unchanged during the study. Depending on the condition of the patient, four types of administration were employed. When necessary the patient was switched from one dosage schedule to the other without the administration of injectable diuretics. The dosage schedules follow: (1) Sixteen tablets per week, i.e., one tablet after each meal and at bedtime on Monday, Tuesday, Thursday and Friday; (2) 32 tablets per week, i.e., two tablets after each meal and at bedtime on Monday, Tuesday, Thursday and Friday; (3) 28 tablets per week, i.e., one tablet after each meal and at bedtime, daily; and (4) 56 tablets per week, i.e., two tablets after each meal and at bedtime, daily.
The experiment was made on 26 patients, of whom 16 were male and 10 were female. Fifteen patients had arteriosclerotic heart disease, eight patients had hypertensive and arteriosclerotic cardiovascular disease, two patients had rheumatic heart disease, inactive, and one patient had syphilitic heart disease.
All patients were observed weekly by one of us. Blood pressures were determined and heart and lung auscultation was carefully checked. During each visit the weight was noted as was the level of peripheral edema and size of the liver. Fluoroscopic examinations of the lungs were made frequently.
All the patients were further studied at regular intervals by means of electrocardiograms, chest roentgenograms, determinations of blood urea nitrogen, and complete blood counts and urinalyses.
When feasible, the diuretic was discontinued and a placebo was substituted. This was done to make certain that we were treating patients who were still in congestive failure. The placebo looked exactly like the original diuretic tablet and the patient was not advised of the change. The Two patients developed diarrhea, but in neither case was it severe enough to necessitate stopping the drug.
One patient had some epigastric distress. This patient had an active duodenal ulcer. He was maintained on his ulcer routine without the necessity of stopping the oral mercurial. One patient with diabetes, on 40 units of neutral protamine Hagedorn insulin daily, had no change in his insulin or dietary requirements while on the oral mercurial tablet. One of the patients in this group found it impossible to take mercurial diuretic injections because of the severe leg cramps which he suffered thereafter. This patient was given a carbonic anhydrase inhibitor and immediately went into heart failure. She was then placed on Merpurate and has been maintained on the drug with complete comfort and compensation.
One patient, while being maintained on the oral drug, needed a prostatectomy. This was performed, and the patient was carried through the entire procedure without the addition of parenteral mercurial diuretics.
Ten patients were given a placebo and all mercurials discontinued. In all cases but one, the patients developed subjective and objective signs of increasing failure. All 9 patients who had developed failure were successfully returned to dry weight with the Merpurate tablets alone ( fig. 1.) .
DISCUSSION
The search for an effective and safe oral mercurial diuretic is not new. Pioneer studies in this field were made by Batterman, DeGraff, and Rose in 1941.5 Their work was followed by further studies with the same and other prod- We have found over a two-year period that Merpurate tablets were capable of replacing the parenteral drugs. In no case was it necessary to replace the oral tablet with parenteral therapy in the group studied. The effectiveness of this product was further established by the use of placebos in nine patients, in order to be certain that these patients still needed mercurials for control of their congestive failure. One of these patients had no diuresis with Diamox, a carbonic anhydrase inhibitor, but had excellent response when placed on the oral mercurial tablet, Merpurate, and was maintained free of failure.
No evidence of renal damage or of mercurial damage elsewhere was noted in any of these patients, in spite of the relatively large intake of mercury over a long period of time.
CONCLUSION
(1) A clinical study was carried out, using Merpurate, a new oral mercurial preparation, in patients, some of whom were maintained on the drug for as long as two years.
(2) Complete replacement of the parenteral drug could be accomplished.
(3) Dosage was an individual problem, but patients in chronic failure could be maintained on dosages ranging from 16 to 56 tablets per week (320 to 1120 mg. of mercury).
(4) There were no important toxic reactions noted. Electrocardiogram, chest x-ray findings, blood chemistry studies, urinalysis and blood count remained unaffected on the dosage of the drug used during the length of the experiment.
(5) From our study it appears that Merpurate is a safe and effective oral diuretic which can replace parenteral therapy in most patients. 
